Subscribe to RSS
Download PDF
DOI: 10.1055/s-0038-1633374
Botulinumtoxin A bei der Migräne
Klinische ErfahrungenBotulinum toxin A in the treatment of migrainePublication History
eingegangen am:
02 July 2013
angenommen am:
01 July 2013
Publication Date:
02 February 2018 (online)
Zusammenfassung
Onabotulinumtoxin ist seit 2011 zur Therapie der chronischen Migräne zugelassen. Die Therapie hat sich bewährt und ist mittlerweile etabliert. Keine andere Therapie hat bei der chronischen Migräne eine Überlegenheit zeigen können. Die Zulassung orientiert sich an den PREEMPT-Zulassungsstudien und gibt Injektionsstellen und Dosierung vor. Weitere Untersuchungen sind notwendig, damit das Injektionsschema optimiert werden kann. Die Zulassung und die positiven Studiendaten beschränken sich auf die chronische Migräne.
Summary
Onabotulinumtoxin A has been approved for the treatment of migraine since 2011. This therapy proved highly successful, has since become well established, and no other therapeutic measure is viewed as superior. The approval is based on the PREEMPT studies and details both injection sites and dosage. Further studies are necessary in order to optimize the injection regimes. Importantly, the approval and the positive studies are limited to the treatment of chronic migraine.
-
Literatur
- 1 Aoki KR, Francis J, Jost WH. Mögliche antinozizeptive Mechanismen von Botulinumtoxin. Schmerz 2006; 20: 381-7.
- 2 Aurora SK, Dodick DW, Turkel CC. et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803.
- 3 Cady RK. Onabotulinumtoxin A in the prevention of migraine. Expert Opin Biol Ther 2010; 10: 289-298.
- 4 Carruthers A, Langtry JA, Carruthers J, Robinson G. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 1999; 39: 662-5.
- 5 Diener HC, Dodick DW, Aurora SK. et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 808-14.
- 6 Dodick DW, Turkel CC, DeGryse RE. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-36.
- 7 Evers S. Status on the use of botulinum toxin for headache disorders. Curr Opin Neurol 2006; 19: 310-5.
- 8 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 01) 9-160.
- 9 Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6.
- 10 Johnston MM, Jordan SE, Charles AC. Pain refferal patterns of the C1-C3 nerves: Implications for headache. Ann Neurol. 2013 doi: 10.1002/ ana.23869.
- 11 Jost WH. Low-dosed botulinum toxin A in the prophylactic management of unilateral migraine: a randomized double-blind placebo-controlled crossover study. Open Pain J 2011; 04: 4-7.
- 12 Mahrhold S, Rummel A, Bigalke H. et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006; 580: 2011-4.
- 13 Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008; 48: 194-200.
- 14 Ramadan NM. Current trends in migraine prophylaxis. Headache. 2007 47. 01 S52-7.
- 15 Relja M, Telaroviæ S. Botulinum toxin in tensiontype headache. J Neurol 2004; 251 (Suppl. 01) I12-4.
- 16 Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000; 40: 445-50.
- 17 Straube A, Gaul C, Förderreuther S. et al. Versorgung von Patienten mit chronischer Migräne. Nervenarzt 2012; 83: 1600-8.
- 18 Truong D, Jost WH. Therapeutical use of botulinum toxin. Parkinsonism Rel Disord 2006; 12: 331-55.